Management of patients with advanced bladder cancer following major response to systemic chemotherapy

Expert Review of Anticancer Therapy

Volumn 9, Issue 12, 2009, Pages 1757-1764

  Yafi, Faysal A ^a   Kassouf, Wassim ^b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Chemotherapy; Metastasectomy; Metastatic bladder cancer; Radiation; Surgical consolidation; Unresectable bladder cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; GEMCITABINE; METHOTREXATE; PACLITAXEL; VINBLASTINE;

ADVANCED CANCER; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CYSTECTOMY; DISEASE FREE SURVIVAL; DRUG CHOICE; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; EVIDENCE BASED MEDICINE; HUMAN; LAPAROTOMY; LUNG METASTASIS; LYMPH NODE METASTASIS; LYMPHADENECTOMY; OUTCOME ASSESSMENT; PARAAORTIC LYMPH NODE; REVIEW; RISK BENEFIT ANALYSIS; SURVIVAL TIME; THORACOTOMY; VISCERAL METASTASIS;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; CYSTECTOMY; DISEASE PROGRESSION; HUMANS; LYMPH NODE EXCISION; NEOPLASM METASTASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 73349136991     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/ERA.09.148     Document Type: Review

References (33)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer Statistics, 2009. CA Cancer J. Clin. 59, 225-249 (2009).
2. Cookson MS, Herr HW, Zhang ZF et al. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J. Urol. 158, 62-67 (1997).
3. Yafi FA, Duclos M, Correa JA et al. Contemporary outcome and management of patients who had an aborted cystectomy due to unresectable bladder cancer. Urol. Oncol. DOI: 10.1016/j. urolonc.2009.04.017 (2009) (Epub ahead of print).
4. Dodd PM, McCaffrey JA, Herr H et al. Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. J. Clin. Oncol. 17, 2546-2552 (1999). Excellent study examining the role of post-chemotherapy surgery in unresectable bladder cancer.
5. Babaian RJ, Johnson DE, Llamas L, Ayala AG et al. Metastases from transitional cell carcinoma of urinary bladder. Urology 16, 142-144 (1980).
6. Yagoda A. Progress in treatment of advanced urothelial tract tumors. J. Clin. Oncol. 3, 1448-1450 (1985).
7. Saxman SB, Propert KJ, Einhorn LH et al. Long-term follow-up of a Phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J. Clin. Oncol. 15, 2564-2569 (1997).
8. Waxman J, Barton C. Carboplatin-based chemotherapy for bladder cancer. Cancer Treat. Rev. 19(Suppl. C), 21-25 (1993).
9. Harker WG, Meyers FJ, Freiha FS et al. Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study. J. Clin. Oncol. 3, 1463-1470 (1985).
10. Loehrer PJ Sr, Einhorn LH, Elson PJ et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J. Clin. Oncol. 10, 1066-1073 (1992).
11. Sternberg CN, Yagoda A, Schar HI et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J. Urol. 133, 403-407 (1985).
12. Logothetis CJ, Dexius FH, Finn L et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J. Clin. Oncol. 8, 1050-1055 (1990).
13. Von der Maase, Sengelow L, Roberts JT et al. Long-term survival results of a randomized trial comparing gemcitabine and cisplatin with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J. Clin. Oncol. 23, 4602-4608 (2005).
14. Sternberg CN, de Mulder PHM, Schornagel JH et al. Randomized Phase III trial of high-dose intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924. J. Clin. Oncol. 19, 2638-2646 (2001).
15. Bamias A, Aravantinos G, Deliveliotis C et al. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, Phase III study from the Hellenic Cooperative Oncology Group. J. Clin. Oncol. 22, 220-228 (2004).
16. Dreicer R, Manola J, Roth BJ et al. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Cancer 100, 1639-1645 (2004).
17. Bellmunt J, Albiol S, Suarez C, Albanell J. Optimizing therapeutic strategies in advanced bladder cancer: update on chemotherapy and the role of targeted agents. Crit. Rev. Oncol. Hematol. 69,211-222 (2009).
18. Dimopoulos MA, Finn L, Logothetis CJ. Pattern of failure and survival of patients with metastatic urothelial tumors relapsing after cis-platinum- based chemotherapy. J. Urol. 151, 598-600 (1994).
19. Sternberg CN, Yagoda A, Scher HI et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Cancer 64,2448-2458 (1989).
20. Herr HW, Donat SM, Bajorin DF. Post-chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer. J. Urol. 165, 811-814 (2001).
21. Donat SM, Herr HW, Bajorin DF et al. Methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy and cystectomy for unresectable bladder cancer. J. Urol. 156, 368-371 (1996).
22. Herr HW, Donat M. Outcome of patients with grossly node positive bladder cancer after pelvic lymph node dissection and radical cystectomy. J. Urol. 165, 62-64 (2001). Good paper showing that presence of gross nodal disease does not preclude surgery.
23. Sweeney P, Millikan R, Donat M et al. Is there a therapeutic role for postchemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder? J. Urol. 169, 2113-2117 (2003). Study showing a possible role for retroperitoneal lymph node dissection in metastatic bladder cancer.
24. De Vries RR, Nieuwenhuijzen JA, Meinhardt W, Bais EM, Horenblas S. Long-term survival after combined modality treatment in metastatic bladder cancer patients presenting with supraregional tumor positive lymph nodes only. Eur. J. Surg. Oncol. 35, 352-355 (2009).
25. Miller RS, Freiha FS, Reese JH, Ozen H, Torti FM. Cisplatin, methotrexate and vinblastine plus surgical restaging for patients with advanced transitional cell carcinoma of the urothelium. J. Urol. 150, 65-69 (1993).
26. Cowles RS, Johnson DE, McMurtrey MJ. Long-term results following thoracotomy for metastatic bladder cancer. Urology 20, 390-392 (1982).
27. Siefker-Radtke AO, Walsh GL, Pisters LL et al. Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience. J. Urol. 171, 145-148 (2004). Important paper showing benefit with visceral metastectomy.
28. Abe T, Shinohara N, Harabayashi T et al. Impact of multimodal treatment on survival in patients with metastatic urothelial cancer. Eur. Urol. 52(4), 1106-1113 (2007).
29. Lehmann J, Suttman H, Albers P et al. Surgery for metastatic urothelial carcinoma with curative intent. The German experience (AUO AB 30/05). Eur. Urol. 55, 1293-1299 (2009).
30. Chang DT, Schellenberg D, Shen J et al. Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer 115, 665-672 (2009).
31. Coen JJ, Zietman AL, Kaufman DS, Shipley WU. Benchmarks achieved in the delivery of radiation therapy for muscleinvasive bladder cancer. Urol. Oncol. 25,76-84 (2007).
32. Passaperuma K, Ash R, Venkatesan V, Rodrigues G, Winquist E. Pelvic chemoradiotherapy after chemotherapy for metastatic bladder cancer. Can. J. Urol. 13, 3009-3015 (2006). Interesting study on the role of consolidation chemoradiotherapy following response to chemotherapy in advanced bladder cancer.
33. Als A, Sengeløv L, von der Maase H. Long-term survival after gemcitabine and cisplatin in patients with locally advanced transitional cell carcinoma of the bladder: focus on supplemental treatment strategies. Eur. J. Urol. 52, 478-487 (2007).